80%
of our sales in clinical applications are from products that contribute to the fight against antimicrobial resistance either directly or indirectly
Our Clinical Solutions for Antimicrobial Resistance
As world leader in microbiology, bioMérieux is dedicated to helping clinical labs provide actionable results faster, because time-to-diagnosis and therapeutic efficacy are paramount to infection control, preventing and managing multi-drug resistance and improving patient outcomes.
A unique and comprehensive range of diagnostic solutions
Our high-medical value diagnostic tests enable timely detection and diagnosis of healthcare-associated and multi-drug resistant infections.
bioMérieux provides clinical laboratories with a comprehensive range of diagnostic solutions for effective screening, infection control, outbreak management and appropriate antibiotic therapy guidance.
Infection Control
Preventing and containing the spread of resistant bacteria in healthcare settings using screening tests, active surveillance, targeted isolation and environmental control systems is primordial to safeguard patients and help manage antibiotic resistance. bioMérieux’s offer covers a wide range of infection control solutions, including:
The CHROMID™ range includes ready-to-use chromogenic culture media for the selective isolation, enumeration and identification of bacteria in 18-24 hours. Chromogenic media deliver more reliable differentiation of pathogens, faster and easier reading of results and enhanced sensitivity and specificity parameters than traditional culture media.
RAPIDEC® CARBA NP is a rapid, high medical value test that confirms the presence of carbapenem resistance by detecting carbapenemase-producing bacteria from a culture. The test detects carbapenemase activity in the most frequently implicated Gram-negative bacteria such as Enterobacteriaceae, P. aeruginosa and A. baumannii in under 2 hours. The rapid detection time ensures that appropriate therapy and isolation measures can be applied as quickly as possible, thereby improving patient management and controlling HAIs.
Environmental Control Solutions include the diagnostic tools required for air, surface and water monitoring (including environmental, hemodialysis and endoscope disinfection control) and Legionella detection.
Pathogen Identification
Identification of the pathogen causing an infection is important to guide diagnosis and antibiotic therapy. bioMérieux covers the entire diagnostic spectrum of infectious diseases, from manual bacteriology tests to automated microbial identification/susceptibility systems to molecular diagnostics.
BIOFIRE® FILMARRAY® is a multiplex PCR system with a total run time of about one hour. The FILMARRAY® platform and its syndromic menu tests for a large variety of bacterial, fungal, viral and parasitic pathogens that cause respiratory, bloodstream, gastrointestinal and meningitis/encephalitis infections, as well as antibiotic resistance genes. Such rapid diagnostic tests that detect pathogens directly from clinical samples (e.g. stools for gastrointestinal infections or cerebrospinal fluid for meningitis/encephalitis infections) give the medical community highly valuable information, such as whether the infection is bacterial, fungal, parasitic or viral, helping to guide the prescription of antibiotics and avoid their misuse.
VITEK® MS is based on MALDI-ToF technology (matrix assisted laser desorption ionization time-of-flight mass spectrometry). VITEK® MS identifies the most common Gram-positive and Gram-negative bacteria and yeasts within minutes. This diagnosis is key to initiating timely and appropriate treatment.
VITEK® 2 is an automated identification/susceptibility testing system capable of identifying the vast majority of routine organisms (over 300 microorganisms). Results can be obtained within hours thanks to the combination of analysis software and an original, miniaturized consumable, the VITEK® 2 card, which is available for a wide range of microorganisms.
For more complex microorganisms, VITEK® 2 can be combined with complementary manual bacteriology methods: the API® range of products for pathogen identification, the ETEST® for antibiotic susceptibility testing and the RAPIDEC® CARBA NP assay for targeted resistance detection.
The API® ID product range is a series of easy-to-use manual identification strips covering almost all groups of commonly occurring bacteria and yeasts isolated from clinical specimens. These standardized, miniaturized strips deliver reliable and accurate pathogen identification to confirm the causative agent and initiate appropriate treatment. The comprehensive APIWEB™ internet database provides interpretive readings for each identification strip.
Antibiotic susceptibility testing
bioMérieux is recognized as the market leader in automated antimicrobial susceptibility testing (AST).
The Company routinely monitors emerging resistance and works with the Clinical & Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) in order to develop the most robust and accurate AST tests possible and maintain up-to-date breakpoints on its flagship VITEK® 2 platform. (ref.114)(https://www.amrindustryalliance.org/wp-content/uploads/2018/01/AMR_Industry_Alliance_Progress_Report_January2018.pdf) More
The VITEK® 2 platform uses its in-built software solution, Advanced Expert System (AES™) to automatically compare every Minimum Inhibitory Concentration (MIC) result to an extensive knowledge base. The AES™ validates the results by expertly interpreting the antibiotic resistance profile of the identified bacteria.
ETEST® is an agar-based antibiotic gradient method that provides antibiotic MIC values and tests a broad range of antimicrobial concentrations. It is the AST solution of choice to help determine the antibiotic concentration required to ensure therapeutic success in hard-to-treat cases: critically ill / immunocompromized patients, life-threatening infections (sepsis, pneumonia, endocarditis, meningitis), challenging organisms (P. aeruginosa, A. baumannii…) and bacteria associated with cystic fibrosis.
RAPIDEC® CARBA NP is a rapid, high medical value test that confirms the presence of carbapenem resistance by detecting carbapenemase-producing bacteria from a culture. The test detects carbapenemase activity in the most frequently implicated Gram-negative bacteria such as Enterobacteriaceae, P. aeruginosa and A. baumannii in under 2 hours. The rapid detection time ensures that appropriate therapy and isolation measures can be applied as quickly as possible, thereby improving patient management and controlling HAIs.
Outbreak management and surveillance
Epidemiological surveillance tools are essential to track, contain and prevent the spread of pathogens at local, hospital, regional, national and international levels. Effective tracking of infectious agents and resistance patterns support the implementation of relevant infection control and antibiotic policies.
The BIOMÉRIEUX EPISEQ®* CS is a WGS**-based epidemiology tool developed for use by hospital epidemiologists and microbiologists to manage suspected HAI-related outbreaks as well as for epidemiological research. The software application provides typing and comparative analysis of bacterial isolates for outbreak detection and epidemiological surveillance.
* Not for diagnostic use
**WGS: Whole Genome Sequencing
The BIOMÉRIEUX EPISEQ® CS service is a WGS-based genomic epidemiology tool developed for hospital epidemiologists and microbiologists to manage healthcare-associated infection (HAI) related outbreaks and also for epidemiological research.
The service provides typing and comparative analysis of bacterial isolates for outbreak detection and epidemiological surveillance. It is fully integrated, allowing users to conduct WGS-based epidemiological analysis of bacterial strains based on their comparison with previous and concurrent strains as well as reference strains.
This software will provide a customized report for the user, presenting precise results in an easily understandable graphical format, and identifying the infectious agent, as well as the sequence-based genetic variations that will assist in understanding its transmission.
Initially focused on Staphylococcus aureus at the time of launch in 2015, the BIOMÉRIEUX EPISEQ® CS menu is expanding to other species commonly linked to HAIs.
> More on BIOMÉRIEUX EPISEQ® – www.biomerieux-episeq.com
MYLA® – IT Performance Management Solutions
MYLA® offers a single software solution to manage multiple instruments and multiple LIS through a unified interface. The right information is easily accessible and flows quickly and securely to those who need it. This solution helps the lab run optimally and deliver complete, reliable information to clinicians supporting patient-care decisions.
> Learn more
Antibiotic prescription guidance
Rationalizing antibiotic prescription to only treat when necessary is crucial in the fight against antibiotic resistance. bioMérieux provides rapid solutions that help determine whether the cause of the infection is bacterial or viral, thereby avoiding unnecessary prescription of antibiotics for viral infections.
VIDAS® B•R•A•H•M•S PCT™ is an automated test adapted for emergency conditions, which determines the level of procalcitonin (PCT) in human serum or plasma in just 20 minutes. PCT is a specific marker for the early detection of severe bacterial infections and sepsis. In February 2017, bioMérieux has received 510(k) clearance from the U.S. FDAFood and Drug Administration More (Food and Drug Administration) for the expanded use of VIDAS® B•R•A•H•M•S PCT™ to help clinicians make important decisions regarding the optimal use of antibiotics in two common clinical situations: lower respiratory tract infections (LRTI) and sepsis. Using VIDAS® B•R•A•H•M•S PCT™ in these frequent and important clinical situations will help reduce inappropriate and unnecessary antibiotic use, which may avoid the side effects associated with their use while slowing and preventing the emergence of resistant bacteria.
Diagnostics and Antimicrobial Stewardship
In vitro diagnostic tests play an essential role in combatting the antibiotic resistance threat. Our extensive Antimicrobial Stewardship (AMS) diagnostics offer supports appropriate antibiotic use, helping to preserve their efficacy and curb antibiotic resistance. Putting diagnostics at the heart of Antimicrobial Stewardship helps drive informed therapy decisions: from antibiotic initiation to optimization and discontinuation.
> Find out more about our clinical solutions for antimicrobial resistance